⏳ Fetching live dividend data...
Home › Calculator › GENE Dividend Calculator 2026
Genetic Technologies Limited · NASDAQ
Price: $0.77 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
GENE is not a dividend-focused stock
GENE pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Genetic Technologies Limited (GENE) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test specifically designed for non-hereditary breast cancer. This innovative test is promoted to various medical specialists, including professionals in breast healthcare and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment experts like breast surgeons. Beyond BREVAGenplus, the company's portfolio includes other cancer risk assessment tests marketed under the 'GeneType' brand, notably 'GeneType for Colorectal Cancer' and 'GeneType for Breast Cancer'. Furthermore, Genetic Technologies is actively developing additional risk assessment tools for a diverse range of conditions, such as cardiovascular diseases, type 2 diabetes, prostate cancer, and melanoma. Its services extend to general genetic testing, encompassing applications in medical, animal, forensic, and plant diagnostics. Genetic Technologies maintains active research and collaboration agreements with several prestigious institutions, including the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, The Ohio State University, and Shivom. The company was established in 1987 and operates from its headquarters in Fitzroy, Australia.
No. Genetic Technologies Limited (GENE) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. GENE has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GENE position with:
Real after-tax yield depends on where you live and how you hold GENE.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
GENE pays quarterly — 4 times per year. Ex-div: —.
How GENE compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GENE sourced from FMP /financial-growth endpoint — real data, not estimates.
Compare GENE with peers: GENE vs AUGX · GENE vs CYT · GENE vs GTH
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GENE dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Genetic Technologies Limited (GENE) is currently trading at $0.77, 79% below its 52-week high. It does not currently pay a regular dividend.
Genetic Technologies Limited (GENE) is a healthcare stock trading at $0.77. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever